The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

It has been established that the metabolism of more than twenty drugs, including antiarrhythmics, beta-adrenoceptor antagonists, antidepressants, opiates and neuroleptics is catalyzed by cytochrome P-450dbl. The activity of this P-450 isozyme is under genetic rather than environmental control. This...

Full description

Saved in:
Bibliographic Details
Published inPharmacology & therapeutics (Oxford) Vol. 46; no. 3; p. 377
Main Authors Eichelbaum, M, Gross, A S
Format Journal Article
LanguageEnglish
Published England 1990
Subjects
Animals
Debrisoquin - metabolism
Humans
Isoquinolines - metabolism
Polymorphism, Genetic
Sparteine - metabolism
Online AccessGet more information

Cover

More Information
Summary:It has been established that the metabolism of more than twenty drugs, including antiarrhythmics, beta-adrenoceptor antagonists, antidepressants, opiates and neuroleptics is catalyzed by cytochrome P-450dbl. The activity of this P-450 isozyme is under genetic rather than environmental control. This article discusses the therapeutic implications for each of the classes of drugs affected by this genetic polymorphism in drug metabolism. Not only are the problems associated with poor metabolizers who are unable to metabolize the compounds discussed, but it is also emphasized that it is difficult to attain therapeutic plasma concentrations for some drugs in high activity extensive metabolizers.
ISSN:0163-7258
1879-016X
DOI:10.1016/0163-7258(90)90025-W